NO20054331L - Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater - Google Patents
Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivaterInfo
- Publication number
- NO20054331L NO20054331L NO20054331A NO20054331A NO20054331L NO 20054331 L NO20054331 L NO 20054331L NO 20054331 A NO20054331 A NO 20054331A NO 20054331 A NO20054331 A NO 20054331A NO 20054331 L NO20054331 L NO 20054331L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl group
- group
- atom
- optionally substituted
- substituted
- Prior art date
Links
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical class O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 150000008318 pyrimidones Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03290728A EP1460076A1 (en) | 2003-03-21 | 2003-03-21 | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| PCT/EP2004/004013 WO2004083210A1 (en) | 2003-03-21 | 2004-03-19 | SUBSTITUTED 8-PERFLUOROALKYL-6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054331D0 NO20054331D0 (no) | 2005-09-20 |
| NO20054331L true NO20054331L (no) | 2005-12-21 |
Family
ID=32799141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054331A NO20054331L (no) | 2003-03-21 | 2005-09-20 | Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7217715B2 (enExample) |
| EP (2) | EP1460076A1 (enExample) |
| JP (1) | JP4572194B2 (enExample) |
| KR (1) | KR101070075B1 (enExample) |
| CN (1) | CN100368412C (enExample) |
| AR (1) | AR053082A1 (enExample) |
| AT (1) | ATE433977T1 (enExample) |
| AU (1) | AU2004222105B2 (enExample) |
| BR (1) | BRPI0408605A (enExample) |
| CA (1) | CA2517774C (enExample) |
| CY (1) | CY1109345T1 (enExample) |
| DE (1) | DE602004021572D1 (enExample) |
| DK (1) | DK1608653T3 (enExample) |
| EA (1) | EA009198B1 (enExample) |
| ES (1) | ES2328812T3 (enExample) |
| IL (1) | IL170634A (enExample) |
| MX (1) | MXPA05010112A (enExample) |
| NO (1) | NO20054331L (enExample) |
| NZ (1) | NZ542224A (enExample) |
| PL (1) | PL1608653T3 (enExample) |
| PT (1) | PT1608653E (enExample) |
| SI (1) | SI1608653T1 (enExample) |
| TW (1) | TWI322809B (enExample) |
| WO (1) | WO2004083210A1 (enExample) |
| ZA (1) | ZA200507192B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
| US8771552B2 (en) * | 2005-06-23 | 2014-07-08 | Sumitomo Electric Industries, Ltd. | Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same |
| JP4277826B2 (ja) | 2005-06-23 | 2009-06-10 | 住友電気工業株式会社 | 窒化物結晶、窒化物結晶基板、エピ層付窒化物結晶基板、ならびに半導体デバイスおよびその製造方法 |
| US9708735B2 (en) | 2005-06-23 | 2017-07-18 | Sumitomo Electric Industries, Ltd. | Group III nitride crystal substrate, epilayer-containing group III nitride crystal substrate, semiconductor device and method of manufacturing the same |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| EP1790649A1 (en) * | 2005-11-21 | 2007-05-30 | Sanofi-Aventis | Substituted bicyclic pyrimidone derivatives |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| EP1939187A1 (en) * | 2006-12-20 | 2008-07-02 | Sanofi-Aventis | Substituted heteroaryl pyridopyrimidone derivatives |
| EP2138492A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidin-4-one derivatives |
| EP2138485A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted N-Oxide pyrazine derivatives |
| EP2138494A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted alkyl pyrimidin-4-one derivatives |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| EP2138495A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted pyrimido[2,1-a]isoquinolin-4-one derivatives |
| EP2138498A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | Substituted tricyclic derivatives against neurodegenerative diseases |
| SI2448940T1 (sl) | 2009-07-02 | 2014-10-30 | Sanofi | Derivati 6,7,8,9-tetrahidro-pirimido(1,2-a)pirimidin-4-ona, njihova priprava in njihova farmacevtska uporaba |
| WO2012085244A1 (fr) | 2010-12-23 | 2012-06-28 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| FR2992316A1 (fr) | 2012-06-22 | 2013-12-27 | Sanofi Sa | Derives de pyrimidinones, leur preparation et leur application en therapeutique |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001270884A (ja) * | 2000-03-23 | 2001-10-02 | Mitsubishi-Tokyo Pharmaceuticals Inc | ピリミドン誘導体 |
| EP1136482A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| ATE269333T1 (de) * | 2000-09-01 | 2004-07-15 | Sanofi Synthelabo | 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate |
| EP1184383A1 (en) * | 2000-09-01 | 2002-03-06 | Sanofi-Synthelabo | 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives |
| EP1460076A1 (en) * | 2003-03-21 | 2004-09-22 | Sanofi-Synthelabo | Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives |
-
2003
- 2003-03-21 EP EP03290728A patent/EP1460076A1/en not_active Withdrawn
-
2004
- 2004-03-17 TW TW093107078A patent/TWI322809B/zh not_active IP Right Cessation
- 2004-03-19 BR BRPI0408605-8A patent/BRPI0408605A/pt not_active IP Right Cessation
- 2004-03-19 DE DE602004021572T patent/DE602004021572D1/de not_active Expired - Lifetime
- 2004-03-19 AU AU2004222105A patent/AU2004222105B2/en not_active Ceased
- 2004-03-19 CA CA2517774A patent/CA2517774C/en not_active Expired - Fee Related
- 2004-03-19 WO PCT/EP2004/004013 patent/WO2004083210A1/en not_active Ceased
- 2004-03-19 SI SI200431223T patent/SI1608653T1/sl unknown
- 2004-03-19 PT PT04721905T patent/PT1608653E/pt unknown
- 2004-03-19 DK DK04721905T patent/DK1608653T3/da active
- 2004-03-19 NZ NZ542224A patent/NZ542224A/en not_active IP Right Cessation
- 2004-03-19 CN CNB2004800120101A patent/CN100368412C/zh not_active Expired - Fee Related
- 2004-03-19 EP EP04721905A patent/EP1608653B1/en not_active Expired - Lifetime
- 2004-03-19 JP JP2006505151A patent/JP4572194B2/ja not_active Expired - Fee Related
- 2004-03-19 AR ARP040100918A patent/AR053082A1/es unknown
- 2004-03-19 EA EA200501311A patent/EA009198B1/ru not_active IP Right Cessation
- 2004-03-19 MX MXPA05010112A patent/MXPA05010112A/es active IP Right Grant
- 2004-03-19 ZA ZA200507192A patent/ZA200507192B/xx unknown
- 2004-03-19 KR KR1020057017571A patent/KR101070075B1/ko not_active Expired - Fee Related
- 2004-03-19 AT AT04721905T patent/ATE433977T1/de active
- 2004-03-19 ES ES04721905T patent/ES2328812T3/es not_active Expired - Lifetime
- 2004-03-19 PL PL04721905T patent/PL1608653T3/pl unknown
-
2005
- 2005-09-01 IL IL170634A patent/IL170634A/en not_active IP Right Cessation
- 2005-09-13 US US11/224,873 patent/US7217715B2/en not_active Expired - Fee Related
- 2005-09-20 NO NO20054331A patent/NO20054331L/no not_active Application Discontinuation
-
2007
- 2007-04-04 US US11/696,256 patent/US7393853B2/en not_active Expired - Fee Related
-
2009
- 2009-09-02 CY CY20091100926T patent/CY1109345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054331L (no) | Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| NO20054330L (no) | 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| TW200510418A (en) | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one derivatives | |
| MX2009006947A (es) | Derivados de pirimidona 6-heterociclica 2-sustituida. | |
| MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
| WO2008078196A3 (en) | Substituted heteroaryl pyridopyrimidone derivatives | |
| NO20071787L (no) | 2-morfolin-4-pyrimidonforbindelse | |
| EA201170095A1 (ru) | Производные (4-пиридин-4-ил)-1h-(1,3,5) триазин-2-она в качестве ингибирования gsk3-бета для лечения нейродегенеративных заболеваний | |
| EA200600196A1 (ru) | Производные замещенного 2-пиримидинил-6,7,8,9-тетрагидропиримидо[1,2-a]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1,2-a]пиримидин-5(1н) она для нейродегенеративных нарушений | |
| DE69727915D1 (de) | Substituierte vinylpyridinderivate und arzneimittel, die diese enthalten | |
| TW200626573A (en) | Pyrimidone compound | |
| NO20041141L (no) | Substituerte 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-A]pyrimidin-4-on og 7-pyridinyl-2,3-dihydroimidazo[1,2-A]pyrimidin-5(1H)on-derivater | |
| WO2007057790A3 (en) | Substituted bicyclic pyrimidone derivatives | |
| EA200400936A1 (ru) | ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| MXPA03002975A (es) | Derivados de 5-amidino-2-hidroxibencenslfonamida, composiciones farmaceuticas que contienen los mismos e intermediarios para su preparacion. | |
| PT1315730E (pt) | Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona | |
| NO20054141L (no) | 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse | |
| CA2236851A1 (en) | Substituted vinylpyridine derivatives and drugs containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |